Table 1.
Baseline patient, disease and treatment characteristics.
| Characteristic | Number (%) |
|---|---|
| Number of patients | 43 |
| Median age (range) | 70 (62–81) |
| Median presenting PSA (range) | 10.5 (3.4–178) |
| Primary tumour T stage | |
| T1 | 13 (31%) |
| T2 | 18 (42%) |
| T3a | 4 (9%) |
| T3b | 7 (16%) |
| T4 | 1 (2%) |
| Primary tumour ISUP grade | |
| 1 | 21 (49%) |
| 2 | 14 (33%) |
| 3 | 4 (9%) |
| 4 | 2 (5%) |
| 5 | 2 (5%) |
| Primary tumour risk category | |
| Low | 13 (30%) |
| Intermediate | 17 (40%) |
| High | 13 (30%) |
| Primary prostate cancer treatment | |
| EBRT | 15 (35%) |
| LDR brachytherapy | 28 (65%) |
| Hormone therapy with primary treatment | |
| None | 26 (60%) |
| 6 months | 5 (12%) |
| 2–3 years | 10 (23%) |
| >3 years | 1 (2%) |
| Unknown | 1 (2%) |